ICD-116B03	SPECIFIC PHOBIA Specific phobia
ICD-10F40.2	Specific (isolated) phobias
DSM-5-TRF40.2xx	Specific Phobia

1. Definition and nosology

Specific phobia (ICD-11: 6B03; DSM-5-TR: F40.2xx) — marked, irrational fear and avoidance of a specific object or situation (animals, blood-injection, heights, flying, enclosed spaces). The patient usually recognizes the fear as excessive.

2. History

• Hippocrates (5th century BC) — descriptions of phobia.
• Westphal C. (1872) — systematic classification.
• Marks I.M. (1969) — systematic desensitization and exposure studies.
• DSM-5 (2013), ICD-11 — subtypes: animal, natural environment, blood-injection-injury, situational, other.

3. Epidemiology

• Lifetime prevalence 7–12% — one of the most common anxiety disorders.
• Sex: 2–3 times higher in females (blood-injection subtype exception — difference small).
• Onset: childhood (animal, blood-injection), young adulthood (situational).

4. Aetiology and pathogenesis

• Heritability ~30% (Hettema 2001).
• Classical conditioning (Watson J.B. ‘Little Albert’, 1920), vicarious learning, information transmission.
• Biological preparedness (Seligman M.E. “preparedness”) — genetic predisposition to certain objects (snakes, spiders).
• In the blood-injection subtype, the vasovagal response (bradycardia, hypotension, loss of consciousness) distinguishes it from other phobias.

5. Clinical features

Subtypes

• Animal — spider, snake, dog, insects.
• Natural environment — heights, water, storms.
• Blood-injection-injury — vasovagal reaction (loss of consciousness characteristic).
• Situational — flight, elevator, tunnel, driving, enclosed place.
• Other — choking, vomiting, clowns, certain sounds.

6. Diagnosis

6.1 Unified diagnostic criteria

A. Acute fear or anxiety about a specific object or situation.

B. Object/situation almost always provokes fear.

C. Enduring with active avoidance or acute distress.

D. Fear is disproportionate to the actual risk.

E. ≥6 months duration (DSM-5-TR).

F. Significant distress or functional impairment.

G. Not better explained by another mental disorder.

6.2 Source-specific clarifications

• DSM-5-TR / ICD-11 — subtype qualifier is mandatory.
• NICE — no separate specific phobia guideline; general anxiety principles.

6.3 Diagnostic algorithm

1. Clinical interview.
2. FSS (Fear Survey Schedule), specific phobia subscales.
3. Functional burden assessment.

6.4 Differential diagnosis

7. Examination and assessment

• FSS, specific phobia scale.
• BAT (Behavioral Avoidance Test) — the degree to which the patient approaches the phobic object.

8. Treatment

1. Exposure therapy is first-line and most effective. Single session 2–3-hour structured exposure (Öst L.G. “one-session treatment”) is effective for most animal and situational phobias.
2. Stepped in vivo exposure — adapted to patient's pace.
3. Virtual Reality Exposure — particularly suitable for flight, height.
4. In the blood-injection subtype — applied tension (Öst) — the patient is taught to tense the muscles, which prevents the vasovagal response.
5. Pharmacotherapy has no primary role; benzodiazepines only for specific events (e.g., pre-flight) as short-term adjunct; may sometimes reduce efficacy of CBT exposure.
6. D-cycloserine adjunct — may enhance exposure efficacy (evidence base developing).

Source-specific specifications

• Öst L.G. — one-session exposure demonstrated 80–90% efficacy (Behav Res Ther 1989).
• Wolitzky-Taylor K.B. et al. Clin Psychol Rev 2008 meta-analysis (33 RCTs) — exposure showed a large effect versus wait-list and a medium effect versus placebo; in vivo contact outperformed other modes of exposure. This meta-analysis made no comparison with pharmacotherapy.
• APA Anxiety Guidelines — exposure first-line.

Treatment methods

1. One-Session Exposure (One-Session Treatment) — Öst (Öst L.G.) — 2–3 hour structured in vivo exposure; 80–90% efficacy for most animal and situational phobias. Öst L.G. Behav Res Ther 1989.
2. Systematic Desensitization (Systematic Desensitization) — Wolpe (Wolpe J.) — Historical method — relaxation + gradual phobic stimulus; superseded by in vivo exposure.
3. Applied Tension (Öst — blood-injection) — Tightening muscles for 10–15 seconds — prevents vasovagal syncope; in specific blood-injection phobia.
4. Virtual Reality Exposure Therapy (VRET — Virtual Reality Exposure Therapy) — For flying, height, spider phobias. Botella C. et al. reviews.
5. D-cycloserine adjunct — NMDA partial agonist; when administered prior to exposure sessions, may enhance extinction learning. Hofmann S.G. et al. review — moderate evidence.

9. Prognosis

• Exposure CBT — majority of patients achieve remission.
• Without treatment, chronicity.

10. Myths and misconceptions

Myth 1: “Specific phobia is only a childhood phobia and does not require treatment in adults”

Evidence: Specific phobia creates functional impairment in adulthood too (avoidance of flying — occupational limitation; avoidance of medical procedures — health risk).

Myth 2: “Forcing the patient into a phobic object causes trauma”

Evidence: appropriately applied stepped exposure is safe and highly effective; with patient consent and pace.

Myth 3: “Hypnotherapy or NLP rapidly cures phobias”

Evidence: systematic evidence base is limited; exposure-based approach is the gold standard.

Myth 4: “A patient can live a normal life by completely avoiding the phobic object”

Evidence: Avoidance strengthens phobia; situational phobias (flight, elevator) create medical and social restrictions.

Myth 5: “Benzodiazepine is an effective treatment for specific situations like flying”

Evidence: Possible short-term adjunct role, but not long-term solution; may reduce CBT/exposure efficacy (state-dependent learning).

11. Sources

1. WHO. ICD-11. 6B03 Specific phobia. 2024.
2. APA. DSM-5-TR. 2022.
3. Öst L.G. One-session treatment for specific phobias. Behav Res Ther 1989;27(1):1–7.
4. Wolitzky-Taylor K.B., Horowitz J.D., Powers M.B., Telch M.J. Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev 2008;28(6):1021–1037.
5. Hettema J.M., Neale M.C., Kendler K.S. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001;158(10):1568–1578.
6. Wolpe J. Psychotherapy by Reciprocal Inhibition. Stanford: Stanford University Press, 1958.
7. Seligman M.E.P. Phobias and preparedness. Behav Ther 1971;2(3):307–320.
8. Hofmann S.G. Enhancing exposure-based therapy from a translational research perspective. Behav Res Ther 2007;45(9):1987–2001.
9. Botella C., Fernández-Álvarez J., Guillén V. et al. Recent progress in virtual reality exposure therapy for phobias: a systematic review. Curr Psychiatry Rep 2017;19(7):42.